{"groups":[{"description":"Patients receive dabrafenib mesylate 150 mg PO BID and trametinib dimethyl sulfoxide 2 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Dabrafenib, Trametinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never Start Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Still on Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"19"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Patient Non Compliance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For subprotocol H, patients with BRAFV600-mutated malignancies were eligible. The mutation status was determined by an NCI-MATCH approved laboratory for 20 patients in this arm. These cases had to be centrally confirmed by the MATCH assay to be usable in the primary analysis.","recruitmentDetails":"Subprotocol H was activated on August 12, 2015, and the expansion cohort was activated on October 2, 2020. Forty-four patients were enrolled on EAY131-H between January 4, 2016, and November 22, 2022. Twenty-four patients were enrolled on the basis of the results from the NCI-MATCH assay, and 20 on the basis of the outside assay results."}